Animal health firm Zoetis Inc (NYSE:ZTS) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the consensus of $1.39.
Adjusted net income for the first quarter of 2025 was $662 million, or $1.48 per diluted share. That’s an increase of 6% and 8%, respectively, on an organic operational basis.
Adjusted net income for the first quarter of 2025 excludes the net impact of $31 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Also Read: Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
The company reported sales of $2.22 billion, up 1% year over year, beating the consensus of $2.19 billion.
On an organic operational basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024.
Revenue in the U.S. segment was $1.2 billion, an increase of 2% compared with the first quarter of 2024 and an increase of 6% on an organic operational basis.
Sales of companion animal products increased by 8%, driven by Simparica Trio, the company’s flea tick and heartworm combination product, key dermatology products Apoquel and Cytopoint, and monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs and Solensia for cats.
Guidance: Zoetis raised its fiscal 2025 revenues guidance from $9.225 billion – $9.375 billion to $9.425 billion – $9.575 billion, compared to the consensus of $9.33 billion.
The company maintains an organic operational growth of 6% to 8%. It expects a reported net income of $2.630 billion—$2.68 billion, compared to prior guidance of $2.57 billion – $2.62 billion.
The animal company raised its adjusted net income guidance to $2.775 billion – $2.825 billion from $2.70 billion and $2.75 billion, with organic operational growth of 6% to 8% (compared to 5% – 7% earlier).
Zoetis forecasts a reported EPS of $5.85 to $5.95 compared to prior guidance of $5.70-$5.80 and adjusted EPS of $6.20-$6.30 from between $6.00 and $6.10, compared to a consensus of $6.09.
The company says the guidance reflects foreign exchange rates as of late April and the impact of enacted tariffs.
Price Action: ZTS stock is down 1.11% at $156.30 during the premarket session at the last check Tuesday.
Read Next:
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。